Oscar Health, Inc. (NYSE: OSCR) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
32.13
+0.15+0.47%
TA
Loading chart...
Snapshot
| Index | - | P/E | 22.95 | EPS (ttm) | 1.40 | Insider Own | 22.73% | Shs Outstand | 259.27M | Perf Week | -1.95% |
| Market Cap | 8.33B | Forward P/E | 16.88 | EPS next Y | 1.90 | Insider Trans | -6.17% | Shs Float | 249.19M | Perf Month | -0.53% |
| Enterprise Value | 206.44M | PEG | 1.52 | EPS next Q | -0.27 | Inst Own | - | Short Float | 6.57% | Perf Quarter | 13.13% |
| Income | 551.00M | P/S | 0.54 | EPS this Y | 23.16% | Inst Trans | - | Short Ratio | 2.72 | Perf Half Y | 141.58% |
| Sales | 15.32B | P/B | 4.05 | EPS next Y | 10.40% | ROA | 4.91% | Short Interest | 16.36M | Perf YTD | 123.59% |
| Book/sh | 7.93 | P/C | 0.97 | EPS next 5Y | 15.14% | ROE | 38.53% | 52W High | 34.48 -6.82% | Perf Year | 80.81% |
| Cash/sh | 33.00 | P/FCF | 1.96 | EPS past 3/5Y | - | ROIC | 22.98% | 52W Low | 10.69 200.56% | Perf 3Y | 404.40% |
| Dividend Est. | - | EV/EBITDA | 0.33 | Sales past 3/5Y | 41.55% 81.75% | Gross Margin | 44.93% | Volatility | 6.20% 5.78% | Perf 5Y | 83.60% |
| Dividend TTM | - | EV/Sales | 0.01 | EPS Y/Y TTM | 1362.90% | Oper. Margin | 4.07% | ATR (14) | 1.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.08 | Sales Y/Y TTM | 66.90% | Profit Margin | 3.60% | RSI (14) | 53.29 | Recom | 2.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.08 | EPS Q/Q | 223.60% | SMA20 | 1.36% | Beta | 2.44 | Target Price | 34.00 |
| Payout | 0.00% | Debt/Eq | 0.44 | Sales Q/Q | 70.39% | SMA50 | 4.55% | Rel Volume | 1.72 | Prev Close | 31.98 |
| Employees | 2,305 | LT Debt/Eq | 0.44 | Earnings | Nov 09 | SMA200 | 51.23% | Avg Volume | 5.49M | Price | 32.13 |
| IPO Date | Mar 03, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 172.96% 1.25% | Net Debt/EBITDA | -5.75 | Volume | 9,446,013 | Change | 0.47% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-18-26 | Reiterated | Raymond James | Outperform | $30 → $42 |
| Sep-17-26 | Reiterated | Piper Sandler | Overweight | $36 → $48 |
| Sep-17-26 | Reiterated | Robert W. Baird | $27 → $33 | |
| Sep-17-26 | Reiterated | Goldman Sachs | Neutral | $30 → $34 |
| Sep-17-26 | Reiterated | UBS | Neutral | $20 → $30 |
| Sep-17-26 | Reiterated | Barclays | Overweight | $39 → $49 |
| Aug-11-26 | Reiterated | Goldman Sachs | Neutral | $22 → $30 |
| Aug-07-26 | Reiterated | Robert W. Baird | $19 → $27 | |
| Jul-28-26 | Reiterated | Piper Sandler | Overweight | $26 → $36 |
| Jun-15-26 | Reiterated | Raymond James | $18 → $30 |
Latest News· Times ET
Sep-18-26
Sep-17-26
Sep-17-2608:08AM
01:40AM
12:11AM
Sep-16-26
10:56AM
04:03AM
Sep-15-26
02:10AM
Sep-14-26
Sep-09-26
Sep-04-26
02:20AM
Company
Oscar Health, Inc. operates as a health insurance provider across the United States. Its offerings include various health plans such as those for individuals and families, small businesses, and Medicare Advantage options. The company also features "+Oscar," a proprietary technology platform designed to facilitate engagement between healthcare providers, payers, and their members or patients. Additionally, Oscar Health provides reinsurance solutions. Originally established as Mulberry Health Inc., the firm officially changed its name to Oscar Health, Inc. in January 2021. It was founded in 2012 and maintains its main office in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15,318 | 11,701 | 9,178 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8,436 | 10,019 | 7,333 | — | — | — | — | — | |
| Gross Profit | 6,882 | 1,682 | 1,845 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,217 | 2,050 | 0 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 5,041 | 29 | 1,788 | — | — | — | — | — | |
| Operating Income | 624 | -396 | 57 | — | — | — | — | — | |
| Interest Expense | 16 | 18 | 24 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -18 | -23 | 0 | — | — | — | — | — | |
| Net Income Before Taxes | 590 | -437 | 33 | — | — | — | — | — | |
| Income Taxes | 39 | 6 | 7 | — | — | — | — | — | |
| Consolidated Net Income | 551 | -443 | 25 | — | — | — | — | — | |
| Net Income From Continuing Operations | 552 | -443 | 26 | — | — | — | — | — | |
| Net Income | 551 | -443 | 25 | — | — | — | — | — | |
| EPS (Recurring) | 1.71 | -1.69 | 0.11 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.71 | -1.69 | 0.11 | — | — | — | — | — | |
| EPS (Diluted) | 1.40 | -1.69 | 0.10 | — | — | — | — | — | |
| EBITDA | 634 | -391 | 89 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 22.95 | — | 140.44 | — | — | — | — | — | |
| Price To Sales Ratio | 0.63 | 0.32 | 0.35 | — | — | — | — | — | |
| Gross Margin | 44.93 | 14.37 | 20.10 | — | — | — | — | — | |
| Operating Margin | 4.07 | -3.38 | 0.62 | — | — | — | — | — | |
| Net Margin | 3.60 | -3.79 | 0.27 | — | — | — | — | — | |
| Shares Outstanding | 302 | 262 | 240 | — | — | — | — | — | |
| Market Capitalization | 9,703 | 3,765 | 3,226 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McAnaney Adam | Chief Legal Officer | Sep 03 '26 | Sale | 31.45 | 9,092 | 285,943 | 209,004 | Sep 08 |
| Liang Janet | President, Oscar Insurance | Sep 03 '26 | Sale | 31.45 | 10,360 | 325,822 | 248,697 | Sep 08 |
| Baltrus Victoria | Chief Accounting Officer | Sep 03 '26 | Sale | 31.45 | 958 | 30,129 | 213,631 | Sep 08 |
| Blackley Richard Scott | Chief Financial Officer | Sep 03 '26 | Sale | 31.45 | 28,869 | 907,930 | 1,046,108 | Sep 08 |
| Schlosser Mario | Director | Sep 03 '26 | Sale | 31.45 | 31,422 | 988,222 | 449,444 | Sep 08 |
| Schlosser Mario | Director | Aug 28 '26 | Option Exercise | 0.00 | 150,000 | 0 | 1,362,293 | Aug 31 |
| Schlosser Mario | Director | Aug 28 '26 | Sale | 30.79 | 150,000 | 4,618,500 | 480,866 | Aug 31 |
| Schlosser Mario | Director | Aug 27 '26 | Sale | 30.34 | 600,000 | 18,204,000 | 480,866 | Aug 31 |
| Schlosser Mario | Director | Aug 27 '26 | Option Exercise | 0.00 | 600,000 | 0 | 1,812,293 | Aug 31 |
| Blackley Richard Scott | Chief Financial Officer | Aug 18 '26 | Sale | 31.74 | 18,750 | 595,125 | 56,250 | Aug 20 |
| Schlosser Mario | Director | Jul 01 '26 | Sale | 31.24 | 47,500 | 1,484,014 | 0 | Jul 06 |
| Bertolini Mark T | Chief Executive Officer | Jun 30 '26 | Sale | 28.48 | 624,244 | 17,781,383 | 7,751,570 | Jul 01 |
| Bertolini Mark T | Chief Executive Officer | Jun 29 '26 | Sale | 29.26 | 614,752 | 17,985,938 | 8,375,814 | Jul 01 |
| Bertolini Mark T | Chief Executive Officer | Jun 26 '26 | Sale | 29.28 | 591,168 | 17,310,761 | 8,990,566 | Jun 29 |
| Bertolini Mark T | Chief Executive Officer | Jun 25 '26 | Sale | 28.61 | 615,142 | 17,601,317 | 9,581,734 | Jun 29 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.